Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 259

1.

Long-term Outcomes of Injection Drug-related Infective Endocarditis Among People Who Inject Drugs.

Suzuki J, Johnson JA, Montgomery MW, Hayden MC, Price CN, Solomon DA, Liebschutz JM, Schnipper JL, Weiss RD.

J Addict Med. 2019 Oct 18. doi: 10.1097/ADM.0000000000000572. [Epub ahead of print]

PMID:
31634202
2.

Suicidal motivations reported by opioid overdose survivors: A cross-sectional study of adults with opioid use disorder.

Connery HS, Taghian N, Kim J, Griffin M, Rockett IRH, Weiss RD, Kathryn McHugh R.

Drug Alcohol Depend. 2019 Oct 5;205:107612. doi: 10.1016/j.drugalcdep.2019.107612. [Epub ahead of print]

PMID:
31627077
3.

Pain catastrophizing and distress intolerance: prediction of pain and emotional stress reactivity.

McHugh RK, Kneeland ET, Edwards RR, Jamison R, Weiss RD.

J Behav Med. 2019 Aug 2. doi: 10.1007/s10865-019-00086-5. [Epub ahead of print]

PMID:
31376099
4.

Time to Reconsider the Role of Craving in Opioid Use Disorder.

Kleykamp BA, Weiss RD, Strain EC.

JAMA Psychiatry. 2019 Jul 24. doi: 10.1001/jamapsychiatry.2019.1839. [Epub ahead of print] No abstract available.

PMID:
31339512
5.

Associations between pain catastrophizing and clinical characteristics in adults with substance use disorders and co-occurring chronic pain.

Kneeland ET, Griffin ML, Taghian N, Weiss RD, McHugh RK.

Am J Drug Alcohol Abuse. 2019;45(5):488-494. doi: 10.1080/00952990.2019.1581793. Epub 2019 Apr 25.

PMID:
31021654
6.

Correlates of Opioid Abstinence in a 42-Month Posttreatment Naturalistic Follow-Up Study of Prescription Opioid Dependence.

Weiss RD, Griffin ML, Marcovitz DE, Hilton BT, Fitzmaurice GM, McHugh RK, Carroll KM.

J Clin Psychiatry. 2019 Mar 26;80(2). pii: 18m12292. doi: 10.4088/JCP.18m12292.

7.

Psychiatric Epidemiology of Transgender and Nonbinary Adult Patients at an Urban Health Center.

Beckwith N, McDowell MJ, Reisner SL, Zaslow S, Weiss RD, Mayer KH, Keuroghlian AS.

LGBT Health. 2019 Feb/Mar;6(2):51-61. doi: 10.1089/lgbt.2018.0136. Epub 2019 Feb 1.

8.

Focus Group Study to Examine Content of Family Meetings in Short-term Substance Use Disorder Treatment.

Faberman J, Provost SE, Weiss RD, Greenfield SF.

J Soc Work Pract Addict. 2018;18(3):231-248. doi: 10.1080/1533256X.2018.1488720. Epub 2018 Jul 11.

9.

Response to commentaries: The quest(ion) remains in the search for a meaningful reduction-based end-point.

Kiluk BD, Fitzmaurice GM, Strain EC, Weiss RD.

Addiction. 2019 Jan;114(1):21-23. doi: 10.1111/add.14491. Epub 2018 Nov 25. No abstract available.

PMID:
30474162
10.

Microscopes and Telescopes: the Societal Impact of Substance Use Disorder Treatment.

Connery HS, Weiss RD.

Am J Psychiatry. 2018 Oct 1;175(10):925-926. doi: 10.1176/appi.ajp.2018.18060694. No abstract available.

PMID:
30269546
11.

Sensitivity analysis for non-monotone missing binary data in longitudinal studies: Application to the NIDA collaborative cocaine treatment study.

Fitzmaurice GM, Lipsitz SR, Weiss RD.

Stat Methods Med Res. 2019 Oct-Nov;28(10-11):3057-3073. doi: 10.1177/0962280218794725. Epub 2018 Aug 27.

PMID:
30146938
12.

Nonmedical benzodiazepine use in adults with alcohol use disorder: The role of anxiety sensitivity and polysubstance use.

McHugh RK, Geyer R, Karakula S, Griffin ML, Weiss RD.

Am J Addict. 2018 Sep;27(6):485-490. doi: 10.1111/ajad.12765. Epub 2018 Jul 20.

PMID:
30028048
13.

Review: Adjunctive pharmacologic approaches for benzodiazepine tapers.

Welsh JW, Tretyak V, McHugh RK, Weiss RD, Bogunovic O.

Drug Alcohol Depend. 2018 Aug 1;189:96-107. doi: 10.1016/j.drugalcdep.2018.04.028. Epub 2018 May 31. Review.

PMID:
29906718
14.

What defines a clinically meaningful outcome in the treatment of substance use disorders: reductions in direct consequences of drug use or improvement in overall functioning?

Kiluk BD, Fitzmaurice GM, Strain EC, Weiss RD.

Addiction. 2019 Jan;114(1):9-15. doi: 10.1111/add.14289. Epub 2018 Jun 27.

PMID:
29900624
15.

Statistical considerations in the choice of endpoint for drug use disorder trials.

Fitzmaurice GM, Lipsitz SR, Weiss RD.

Drug Alcohol Depend. 2017 Dec 1;181:219-222. doi: 10.1016/j.drugalcdep.2017.09.031. Epub 2017 Oct 18.

16.

Nabilone pharmacotherapy for cannabis dependence: A randomized, controlled pilot study.

Hill KP, Palastro MD, Gruber SA, Fitzmaurice GM, Greenfield SF, Lukas SE, Weiss RD.

Am J Addict. 2017 Dec;26(8):795-801. doi: 10.1111/ajad.12622. Epub 2017 Sep 18.

17.

Religious coping in patients with severe substance use disorders receiving acute inpatient detoxification.

Medlock MM, Rosmarin DH, Connery HS, Griffin ML, Weiss RD, Karakula SL, McHugh RK.

Am J Addict. 2017 Oct;26(7):744-750. doi: 10.1111/ajad.12606. Epub 2017 Aug 24.

18.

Improving Adherence to Long-term Opioid Therapy Guidelines to Reduce Opioid Misuse in Primary Care: A Cluster-Randomized Clinical Trial.

Liebschutz JM, Xuan Z, Shanahan CW, LaRochelle M, Keosaian J, Beers D, Guara G, O'Connor K, Alford DP, Parker V, Weiss RD, Samet JH, Crosson J, Cushman PA, Lasser KE.

JAMA Intern Med. 2017 Sep 1;177(9):1265-1272. doi: 10.1001/jamainternmed.2017.2468.

19.

Development of an integrated cognitive behavioral therapy for anxiety and opioid use disorder: Study protocol and methods.

McHugh RK, Votaw VR, Barlow DH, Fitzmaurice GM, Greenfield SF, Weiss RD.

Contemp Clin Trials. 2017 Sep;60:105-112. doi: 10.1016/j.cct.2017.07.006. Epub 2017 Jul 8.

20.

Addiction-25 Years Later.

Greenfield SF, Weiss RD.

Harv Rev Psychiatry. 2017 May/Jun;25(3):97-100. doi: 10.1097/HRP.0000000000000159. No abstract available.

Supplemental Content

Loading ...
Support Center